nodes	percent_of_prediction	percent_of_DWPC	metapath
Nimodipine—CYP3A5—Paclitaxel—ovarian cancer	0.0362	0.253	CbGbCtD
Nimodipine—CYP3A4—Topotecan—ovarian cancer	0.0285	0.2	CbGbCtD
Nimodipine—CYP3A5—Docetaxel—ovarian cancer	0.0262	0.183	CbGbCtD
Nimodipine—CYP3A4—Vinorelbine—ovarian cancer	0.0201	0.141	CbGbCtD
Nimodipine—CYP3A4—Paclitaxel—ovarian cancer	0.0141	0.0988	CbGbCtD
Nimodipine—CACNB3—myometrium—ovarian cancer	0.0108	0.0469	CbGeAlD
Nimodipine—CYP3A4—Docetaxel—ovarian cancer	0.0102	0.0714	CbGbCtD
Nimodipine—CACNB3—uterine cervix—ovarian cancer	0.00843	0.0365	CbGeAlD
Nimodipine—CACNB3—decidua—ovarian cancer	0.00803	0.0348	CbGeAlD
Nimodipine—AHR—myometrium—ovarian cancer	0.00802	0.0348	CbGeAlD
Nimodipine—CACNB3—endometrium—ovarian cancer	0.00762	0.033	CbGeAlD
Nimodipine—CYP3A4—Doxorubicin—ovarian cancer	0.00762	0.0532	CbGbCtD
Nimodipine—CACNB4—vagina—ovarian cancer	0.00746	0.0323	CbGeAlD
Nimodipine—CACNB3—uterus—ovarian cancer	0.00703	0.0304	CbGeAlD
Nimodipine—CACNB4—testis—ovarian cancer	0.00665	0.0288	CbGeAlD
Nimodipine—CACNB3—female reproductive system—ovarian cancer	0.00632	0.0274	CbGeAlD
Nimodipine—AHR—uterine cervix—ovarian cancer	0.00624	0.0271	CbGeAlD
Nimodipine—CACNB1—female gonad—ovarian cancer	0.00599	0.026	CbGeAlD
Nimodipine—AHR—decidua—ovarian cancer	0.00595	0.0258	CbGeAlD
Nimodipine—CACNA1C—myometrium—ovarian cancer	0.00587	0.0254	CbGeAlD
Nimodipine—CACNB3—female gonad—ovarian cancer	0.00575	0.0249	CbGeAlD
Nimodipine—CACNB3—vagina—ovarian cancer	0.00571	0.0248	CbGeAlD
Nimodipine—AHR—endometrium—ovarian cancer	0.00565	0.0245	CbGeAlD
Nimodipine—NR3C2—myometrium—ovarian cancer	0.00534	0.0232	CbGeAlD
Nimodipine—CACNB1—testis—ovarian cancer	0.00531	0.023	CbGeAlD
Nimodipine—AHR—uterus—ovarian cancer	0.0052	0.0226	CbGeAlD
Nimodipine—CACNB3—testis—ovarian cancer	0.0051	0.0221	CbGeAlD
Nimodipine—CACNA1D—uterine cervix—ovarian cancer	0.00495	0.0215	CbGeAlD
Nimodipine—AHR—female reproductive system—ovarian cancer	0.00468	0.0203	CbGeAlD
Nimodipine—AHR—bone marrow—ovarian cancer	0.00442	0.0191	CbGeAlD
Nimodipine—CACNA1C—decidua—ovarian cancer	0.00435	0.0189	CbGeAlD
Nimodipine—AHR—female gonad—ovarian cancer	0.00426	0.0185	CbGeAlD
Nimodipine—AHR—vagina—ovarian cancer	0.00423	0.0183	CbGeAlD
Nimodipine—NR3C2—uterine cervix—ovarian cancer	0.00416	0.018	CbGeAlD
Nimodipine—CACNB1—lymph node—ovarian cancer	0.00385	0.0167	CbGeAlD
Nimodipine—CACNB2—vagina—ovarian cancer	0.00384	0.0166	CbGeAlD
Nimodipine—AHR—testis—ovarian cancer	0.00378	0.0164	CbGeAlD
Nimodipine—NR3C2—endometrium—ovarian cancer	0.00376	0.0163	CbGeAlD
Nimodipine—CACNB3—lymph node—ovarian cancer	0.00369	0.016	CbGeAlD
Nimodipine—NR3C2—uterus—ovarian cancer	0.00347	0.015	CbGeAlD
Nimodipine—CACNB2—testis—ovarian cancer	0.00342	0.0148	CbGeAlD
Nimodipine—CACNA1C—female reproductive system—ovarian cancer	0.00342	0.0148	CbGeAlD
Nimodipine—NR3C2—female reproductive system—ovarian cancer	0.00312	0.0135	CbGeAlD
Nimodipine—CACNA1C—vagina—ovarian cancer	0.0031	0.0134	CbGeAlD
Nimodipine—CACNA1D—testis—ovarian cancer	0.00299	0.013	CbGeAlD
Nimodipine—Ileus—Docetaxel—ovarian cancer	0.00298	0.00839	CcSEcCtD
Nimodipine—Nausea—Altretamine—ovarian cancer	0.00289	0.00815	CcSEcCtD
Nimodipine—NR3C2—female gonad—ovarian cancer	0.00284	0.0123	CbGeAlD
Nimodipine—Liver function test abnormal—Melphalan—ovarian cancer	0.00283	0.00799	CcSEcCtD
Nimodipine—Cramp muscle—Topotecan—ovarian cancer	0.00282	0.00796	CcSEcCtD
Nimodipine—NR3C2—vagina—ovarian cancer	0.00282	0.0122	CbGeAlD
Nimodipine—Lactic dehydrogenase activity increased—Epirubicin—ovarian cancer	0.00278	0.00783	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Topotecan—ovarian cancer	0.00277	0.00779	CcSEcCtD
Nimodipine—CACNA1C—testis—ovarian cancer	0.00276	0.012	CbGeAlD
Nimodipine—AHR—lymph node—ovarian cancer	0.00274	0.0119	CbGeAlD
Nimodipine—Hyponatraemia—Vinorelbine—ovarian cancer	0.00269	0.00759	CcSEcCtD
Nimodipine—Jaundice—Chlorambucil—ovarian cancer	0.00265	0.00746	CcSEcCtD
Nimodipine—Lactic dehydrogenase activity increased—Doxorubicin—ovarian cancer	0.00257	0.00724	CcSEcCtD
Nimodipine—NR3C2—testis—ovarian cancer	0.00251	0.0109	CbGeAlD
Nimodipine—Phosphatase alkaline increased—Paclitaxel—ovarian cancer	0.00249	0.00701	CcSEcCtD
Nimodipine—CACNB2—lymph node—ovarian cancer	0.00248	0.0108	CbGeAlD
Nimodipine—Blood lactate dehydrogenase increased—Epirubicin—ovarian cancer	0.00244	0.00689	CcSEcCtD
Nimodipine—Wheezing—Paclitaxel—ovarian cancer	0.00241	0.0068	CcSEcCtD
Nimodipine—Fluid retention—Paclitaxel—ovarian cancer	0.00236	0.00665	CcSEcCtD
Nimodipine—Jaundice—Melphalan—ovarian cancer	0.00231	0.0065	CcSEcCtD
Nimodipine—Hepatobiliary disease—Topotecan—ovarian cancer	0.00228	0.00644	CcSEcCtD
Nimodipine—Blood lactate dehydrogenase increased—Doxorubicin—ovarian cancer	0.00226	0.00638	CcSEcCtD
Nimodipine—CYP3A5—uterine cervix—ovarian cancer	0.00225	0.00974	CbGeAlD
Nimodipine—Hepatobiliary disease—Melphalan—ovarian cancer	0.00224	0.00631	CcSEcCtD
Nimodipine—Lightheadedness—Paclitaxel—ovarian cancer	0.00222	0.00627	CcSEcCtD
Nimodipine—CACNA1D—lymph node—ovarian cancer	0.00217	0.0094	CbGeAlD
Nimodipine—Hepatitis—Melphalan—ovarian cancer	0.00212	0.00599	CcSEcCtD
Nimodipine—Phosphatase alkaline increased—Docetaxel—ovarian cancer	0.00211	0.00594	CcSEcCtD
Nimodipine—Phlebitis—Paclitaxel—ovarian cancer	0.00209	0.0059	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Paclitaxel—ovarian cancer	0.00207	0.00585	CcSEcCtD
Nimodipine—Ileus—Epirubicin—ovarian cancer	0.00201	0.00566	CcSEcCtD
Nimodipine—CACNA1C—lymph node—ovarian cancer	0.002	0.00868	CbGeAlD
Nimodipine—Fluid retention—Docetaxel—ovarian cancer	0.002	0.00564	CcSEcCtD
Nimodipine—Cardiac failure congestive—Paclitaxel—ovarian cancer	0.00199	0.00561	CcSEcCtD
Nimodipine—Flushing—Melphalan—ovarian cancer	0.00197	0.00556	CcSEcCtD
Nimodipine—Angiopathy—Topotecan—ovarian cancer	0.00197	0.00555	CcSEcCtD
Nimodipine—Anaemia—Chlorambucil—ovarian cancer	0.00196	0.00553	CcSEcCtD
Nimodipine—Immune system disorder—Topotecan—ovarian cancer	0.00196	0.00552	CcSEcCtD
Nimodipine—Hepatobiliary disease—Vinorelbine—ovarian cancer	0.00195	0.00551	CcSEcCtD
Nimodipine—Immune system disorder—Melphalan—ovarian cancer	0.00192	0.00541	CcSEcCtD
Nimodipine—Lightheadedness—Docetaxel—ovarian cancer	0.00188	0.00531	CcSEcCtD
Nimodipine—Ileus—Doxorubicin—ovarian cancer	0.00186	0.00524	CcSEcCtD
Nimodipine—NR3C2—lymph node—ovarian cancer	0.00182	0.0079	CbGeAlD
Nimodipine—Muscle spasms—Topotecan—ovarian cancer	0.00182	0.00512	CcSEcCtD
Nimodipine—Hyponatraemia—Paclitaxel—ovarian cancer	0.00181	0.00511	CcSEcCtD
Nimodipine—Phlebitis—Docetaxel—ovarian cancer	0.00177	0.005	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Docetaxel—ovarian cancer	0.00176	0.00496	CcSEcCtD
Nimodipine—Anaemia—Topotecan—ovarian cancer	0.00175	0.00492	CcSEcCtD
Nimodipine—Cardiac disorder—Vinorelbine—ovarian cancer	0.00172	0.00485	CcSEcCtD
Nimodipine—Flushing—Vinorelbine—ovarian cancer	0.00172	0.00485	CcSEcCtD
Nimodipine—Anaemia—Melphalan—ovarian cancer	0.00171	0.00482	CcSEcCtD
Nimodipine—Thrombocytopenia—Chlorambucil—ovarian cancer	0.00169	0.00478	CcSEcCtD
Nimodipine—Cardiac failure congestive—Docetaxel—ovarian cancer	0.00169	0.00475	CcSEcCtD
Nimodipine—Angiopathy—Vinorelbine—ovarian cancer	0.00168	0.00475	CcSEcCtD
Nimodipine—Immune system disorder—Vinorelbine—ovarian cancer	0.00168	0.00472	CcSEcCtD
Nimodipine—Liver function test abnormal—Paclitaxel—ovarian cancer	0.00167	0.00469	CcSEcCtD
Nimodipine—Cramp muscle—Paclitaxel—ovarian cancer	0.00162	0.00458	CcSEcCtD
Nimodipine—Myalgia—Topotecan—ovarian cancer	0.00161	0.00453	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Paclitaxel—ovarian cancer	0.00159	0.00448	CcSEcCtD
Nimodipine—Myalgia—Melphalan—ovarian cancer	0.00157	0.00444	CcSEcCtD
Nimodipine—Hyponatraemia—Docetaxel—ovarian cancer	0.00154	0.00433	CcSEcCtD
Nimodipine—CYP3A5—female gonad—ovarian cancer	0.00153	0.00664	CbGeAlD
Nimodipine—Gastrointestinal haemorrhage—Docetaxel—ovarian cancer	0.00153	0.00431	CcSEcCtD
Nimodipine—CYP3A5—vagina—ovarian cancer	0.00152	0.0066	CbGeAlD
Nimodipine—Sweating increased—Paclitaxel—ovarian cancer	0.00152	0.00428	CcSEcCtD
Nimodipine—Nervous system disorder—Topotecan—ovarian cancer	0.00151	0.00426	CcSEcCtD
Nimodipine—Oedema—Melphalan—ovarian cancer	0.00151	0.00425	CcSEcCtD
Nimodipine—Thrombocytopenia—Topotecan—ovarian cancer	0.00151	0.00425	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00149	0.00421	CcSEcCtD
Nimodipine—Anaemia—Vinorelbine—ovarian cancer	0.00149	0.00421	CcSEcCtD
Nimodipine—Hyperhidrosis—Topotecan—ovarian cancer	0.00149	0.0042	CcSEcCtD
Nimodipine—Thrombocytopenia—Melphalan—ovarian cancer	0.00148	0.00416	CcSEcCtD
Nimodipine—Tachycardia—Melphalan—ovarian cancer	0.00147	0.00415	CcSEcCtD
Nimodipine—Palpitations—Vinorelbine—ovarian cancer	0.00143	0.00402	CcSEcCtD
Nimodipine—Phosphatase alkaline increased—Epirubicin—ovarian cancer	0.00142	0.00401	CcSEcCtD
Nimodipine—Liver function test abnormal—Docetaxel—ovarian cancer	0.00141	0.00398	CcSEcCtD
Nimodipine—Hypotension—Melphalan—ovarian cancer	0.00141	0.00397	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.0014	0.00396	CcSEcCtD
Nimodipine—Hypertension—Vinorelbine—ovarian cancer	0.00139	0.00393	CcSEcCtD
Nimodipine—Depression—Paclitaxel—ovarian cancer	0.00139	0.00391	CcSEcCtD
Nimodipine—Cramp muscle—Docetaxel—ovarian cancer	0.00138	0.00388	CcSEcCtD
Nimodipine—Myalgia—Vinorelbine—ovarian cancer	0.00138	0.00388	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.00137	0.00387	CcSEcCtD
Nimodipine—Dyspnoea—Topotecan—ovarian cancer	0.00137	0.00387	CcSEcCtD
Nimodipine—Fluid retention—Epirubicin—ovarian cancer	0.00135	0.0038	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Docetaxel—ovarian cancer	0.00135	0.0038	CcSEcCtD
Nimodipine—Dyspnoea—Melphalan—ovarian cancer	0.00135	0.00379	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00133	0.00375	CcSEcCtD
Nimodipine—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.00131	0.00371	CcSEcCtD
Nimodipine—Phosphatase alkaline increased—Doxorubicin—ovarian cancer	0.00131	0.00371	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.0013	0.00367	CcSEcCtD
Nimodipine—Nervous system disorder—Vinorelbine—ovarian cancer	0.00129	0.00364	CcSEcCtD
Nimodipine—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00129	0.00364	CcSEcCtD
Nimodipine—Tachycardia—Vinorelbine—ovarian cancer	0.00129	0.00363	CcSEcCtD
Nimodipine—Hypersensitivity—Chlorambucil—ovarian cancer	0.00128	0.00359	CcSEcCtD
Nimodipine—Bradycardia—Paclitaxel—ovarian cancer	0.00127	0.00358	CcSEcCtD
Nimodipine—CYP3A4—female reproductive system—ovarian cancer	0.00126	0.00548	CbGeAlD
Nimodipine—Fluid retention—Doxorubicin—ovarian cancer	0.00125	0.00352	CcSEcCtD
Nimodipine—Hypotension—Vinorelbine—ovarian cancer	0.00123	0.00347	CcSEcCtD
Nimodipine—Pruritus—Chlorambucil—ovarian cancer	0.00122	0.00345	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.0012	0.00339	CcSEcCtD
Nimodipine—Phlebitis—Epirubicin—ovarian cancer	0.0012	0.00337	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Epirubicin—ovarian cancer	0.00119	0.00334	CcSEcCtD
Nimodipine—Diarrhoea—Chlorambucil—ovarian cancer	0.00118	0.00334	CcSEcCtD
Nimodipine—Dyspnoea—Vinorelbine—ovarian cancer	0.00118	0.00331	CcSEcCtD
Nimodipine—Cardiac disorder—Paclitaxel—ovarian cancer	0.00116	0.00326	CcSEcCtD
Nimodipine—Flushing—Paclitaxel—ovarian cancer	0.00116	0.00326	CcSEcCtD
Nimodipine—Jaundice—Docetaxel—ovarian cancer	0.00115	0.00324	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00114	0.00321	CcSEcCtD
Nimodipine—Cardiac failure congestive—Epirubicin—ovarian cancer	0.00114	0.00321	CcSEcCtD
Nimodipine—Hypersensitivity—Topotecan—ovarian cancer	0.00114	0.0032	CcSEcCtD
Nimodipine—Angiopathy—Paclitaxel—ovarian cancer	0.00113	0.00319	CcSEcCtD
Nimodipine—Immune system disorder—Paclitaxel—ovarian cancer	0.00113	0.00318	CcSEcCtD
Nimodipine—Hepatobiliary disease—Docetaxel—ovarian cancer	0.00111	0.00314	CcSEcCtD
Nimodipine—Hypersensitivity—Melphalan—ovarian cancer	0.00111	0.00313	CcSEcCtD
Nimodipine—Phlebitis—Doxorubicin—ovarian cancer	0.00111	0.00312	CcSEcCtD
Nimodipine—Vomiting—Chlorambucil—ovarian cancer	0.0011	0.0031	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Doxorubicin—ovarian cancer	0.0011	0.00309	CcSEcCtD
Nimodipine—Pruritus—Topotecan—ovarian cancer	0.00109	0.00307	CcSEcCtD
Nimodipine—Pruritus—Melphalan—ovarian cancer	0.00107	0.00301	CcSEcCtD
Nimodipine—Hepatitis—Docetaxel—ovarian cancer	0.00106	0.00298	CcSEcCtD
Nimodipine—Diarrhoea—Topotecan—ovarian cancer	0.00105	0.00297	CcSEcCtD
Nimodipine—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.00105	0.00297	CcSEcCtD
Nimodipine—Muscle spasms—Paclitaxel—ovarian cancer	0.00104	0.00294	CcSEcCtD
Nimodipine—Hyponatraemia—Epirubicin—ovarian cancer	0.00104	0.00292	CcSEcCtD
Nimodipine—Diarrhoea—Melphalan—ovarian cancer	0.00103	0.00291	CcSEcCtD
Nimodipine—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.00103	0.00291	CcSEcCtD
Nimodipine—Nausea—Chlorambucil—ovarian cancer	0.00103	0.0029	CcSEcCtD
Nimodipine—Dizziness—Topotecan—ovarian cancer	0.00102	0.00287	CcSEcCtD
Nimodipine—Anaemia—Paclitaxel—ovarian cancer	0.001	0.00283	CcSEcCtD
Nimodipine—Cardiac disorder—Docetaxel—ovarian cancer	0.000982	0.00277	CcSEcCtD
Nimodipine—Flushing—Docetaxel—ovarian cancer	0.000982	0.00277	CcSEcCtD
Nimodipine—Vomiting—Topotecan—ovarian cancer	0.00098	0.00276	CcSEcCtD
Nimodipine—Rash—Topotecan—ovarian cancer	0.000972	0.00274	CcSEcCtD
Nimodipine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000971	0.00274	CcSEcCtD
Nimodipine—Dermatitis—Topotecan—ovarian cancer	0.000971	0.00274	CcSEcCtD
Nimodipine—Headache—Topotecan—ovarian cancer	0.000965	0.00272	CcSEcCtD
Nimodipine—Palpitations—Paclitaxel—ovarian cancer	0.00096	0.00271	CcSEcCtD
Nimodipine—Angiopathy—Docetaxel—ovarian cancer	0.00096	0.00271	CcSEcCtD
Nimodipine—Vomiting—Melphalan—ovarian cancer	0.000959	0.0027	CcSEcCtD
Nimodipine—Hyponatraemia—Doxorubicin—ovarian cancer	0.000958	0.0027	CcSEcCtD
Nimodipine—Immune system disorder—Docetaxel—ovarian cancer	0.000955	0.00269	CcSEcCtD
Nimodipine—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.000954	0.00269	CcSEcCtD
Nimodipine—Liver function test abnormal—Epirubicin—ovarian cancer	0.000952	0.00268	CcSEcCtD
Nimodipine—Rash—Melphalan—ovarian cancer	0.000951	0.00268	CcSEcCtD
Nimodipine—Dermatitis—Melphalan—ovarian cancer	0.00095	0.00268	CcSEcCtD
Nimodipine—Hypertension—Paclitaxel—ovarian cancer	0.000938	0.00264	CcSEcCtD
Nimodipine—Pruritus—Vinorelbine—ovarian cancer	0.000933	0.00263	CcSEcCtD
Nimodipine—Myalgia—Paclitaxel—ovarian cancer	0.000925	0.00261	CcSEcCtD
Nimodipine—Nausea—Topotecan—ovarian cancer	0.000915	0.00258	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.00091	0.00256	CcSEcCtD
Nimodipine—Diarrhoea—Vinorelbine—ovarian cancer	0.000902	0.00254	CcSEcCtD
Nimodipine—Nausea—Melphalan—ovarian cancer	0.000896	0.00253	CcSEcCtD
Nimodipine—Oedema—Paclitaxel—ovarian cancer	0.000887	0.0025	CcSEcCtD
Nimodipine—Muscle spasms—Docetaxel—ovarian cancer	0.000885	0.0025	CcSEcCtD
Nimodipine—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000881	0.00248	CcSEcCtD
Nimodipine—Dizziness—Vinorelbine—ovarian cancer	0.000872	0.00246	CcSEcCtD
Nimodipine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000869	0.00245	CcSEcCtD
Nimodipine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000868	0.00245	CcSEcCtD
Nimodipine—Tachycardia—Paclitaxel—ovarian cancer	0.000865	0.00244	CcSEcCtD
Nimodipine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000857	0.00242	CcSEcCtD
Nimodipine—Anaemia—Docetaxel—ovarian cancer	0.000851	0.0024	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000842	0.00237	CcSEcCtD
Nimodipine—Vomiting—Vinorelbine—ovarian cancer	0.000838	0.00236	CcSEcCtD
Nimodipine—Rash—Vinorelbine—ovarian cancer	0.000831	0.00234	CcSEcCtD
Nimodipine—Dermatitis—Vinorelbine—ovarian cancer	0.00083	0.00234	CcSEcCtD
Nimodipine—Hypotension—Paclitaxel—ovarian cancer	0.000828	0.00234	CcSEcCtD
Nimodipine—Headache—Vinorelbine—ovarian cancer	0.000826	0.00233	CcSEcCtD
Nimodipine—Palpitations—Docetaxel—ovarian cancer	0.000814	0.00229	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000808	0.00228	CcSEcCtD
Nimodipine—Hypertension—Docetaxel—ovarian cancer	0.000795	0.00224	CcSEcCtD
Nimodipine—Dyspnoea—Paclitaxel—ovarian cancer	0.00079	0.00223	CcSEcCtD
Nimodipine—Myalgia—Docetaxel—ovarian cancer	0.000784	0.00221	CcSEcCtD
Nimodipine—Nausea—Vinorelbine—ovarian cancer	0.000783	0.00221	CcSEcCtD
Nimodipine—Jaundice—Epirubicin—ovarian cancer	0.000775	0.00218	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000765	0.00216	CcSEcCtD
Nimodipine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000752	0.00212	CcSEcCtD
Nimodipine—Oedema—Docetaxel—ovarian cancer	0.000752	0.00212	CcSEcCtD
Nimodipine—Nervous system disorder—Docetaxel—ovarian cancer	0.000737	0.00208	CcSEcCtD
Nimodipine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000736	0.00207	CcSEcCtD
Nimodipine—Tachycardia—Docetaxel—ovarian cancer	0.000733	0.00207	CcSEcCtD
Nimodipine—Bradycardia—Epirubicin—ovarian cancer	0.000726	0.00205	CcSEcCtD
Nimodipine—Jaundice—Doxorubicin—ovarian cancer	0.000717	0.00202	CcSEcCtD
Nimodipine—Hepatitis—Epirubicin—ovarian cancer	0.000713	0.00201	CcSEcCtD
Nimodipine—Hypotension—Docetaxel—ovarian cancer	0.000702	0.00198	CcSEcCtD
Nimodipine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000695	0.00196	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000685	0.00193	CcSEcCtD
Nimodipine—Nisoldipine—ABCB1—ovarian cancer	0.000684	0.203	CrCbGaD
Nimodipine—Bradycardia—Doxorubicin—ovarian cancer	0.000672	0.00189	CcSEcCtD
Nimodipine—Dyspnoea—Docetaxel—ovarian cancer	0.00067	0.00189	CcSEcCtD
Nimodipine—Cardiac disorder—Epirubicin—ovarian cancer	0.000662	0.00187	CcSEcCtD
Nimodipine—Flushing—Epirubicin—ovarian cancer	0.000662	0.00187	CcSEcCtD
Nimodipine—Hepatitis—Doxorubicin—ovarian cancer	0.00066	0.00186	CcSEcCtD
Nimodipine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000653	0.00184	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000649	0.00183	CcSEcCtD
Nimodipine—Angiopathy—Epirubicin—ovarian cancer	0.000647	0.00182	CcSEcCtD
Nimodipine—Immune system disorder—Epirubicin—ovarian cancer	0.000644	0.00182	CcSEcCtD
Nimodipine—Nitrendipine—ABCB1—ovarian cancer	0.00064	0.19	CrCbGaD
Nimodipine—Pruritus—Paclitaxel—ovarian cancer	0.000627	0.00177	CcSEcCtD
Nimodipine—Flushing—Doxorubicin—ovarian cancer	0.000613	0.00173	CcSEcCtD
Nimodipine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000613	0.00173	CcSEcCtD
Nimodipine—Diarrhoea—Paclitaxel—ovarian cancer	0.000607	0.00171	CcSEcCtD
Nimodipine—Angiopathy—Doxorubicin—ovarian cancer	0.000599	0.00169	CcSEcCtD
Nimodipine—Muscle spasms—Epirubicin—ovarian cancer	0.000597	0.00168	CcSEcCtD
Nimodipine—Immune system disorder—Doxorubicin—ovarian cancer	0.000596	0.00168	CcSEcCtD
Nimodipine—Dizziness—Paclitaxel—ovarian cancer	0.000586	0.00165	CcSEcCtD
Nimodipine—Anaemia—Epirubicin—ovarian cancer	0.000574	0.00162	CcSEcCtD
Nimodipine—Vomiting—Paclitaxel—ovarian cancer	0.000564	0.00159	CcSEcCtD
Nimodipine—Rash—Paclitaxel—ovarian cancer	0.000559	0.00158	CcSEcCtD
Nimodipine—Dermatitis—Paclitaxel—ovarian cancer	0.000559	0.00157	CcSEcCtD
Nimodipine—Headache—Paclitaxel—ovarian cancer	0.000555	0.00157	CcSEcCtD
Nimodipine—Hypersensitivity—Docetaxel—ovarian cancer	0.000554	0.00156	CcSEcCtD
Nimodipine—Muscle spasms—Doxorubicin—ovarian cancer	0.000553	0.00156	CcSEcCtD
Nimodipine—Amlodipine—ABCB1—ovarian cancer	0.000551	0.164	CrCbGaD
Nimodipine—Palpitations—Epirubicin—ovarian cancer	0.000549	0.00155	CcSEcCtD
Nimodipine—Hypertension—Epirubicin—ovarian cancer	0.000536	0.00151	CcSEcCtD
Nimodipine—Pruritus—Docetaxel—ovarian cancer	0.000532	0.0015	CcSEcCtD
Nimodipine—Anaemia—Doxorubicin—ovarian cancer	0.000531	0.0015	CcSEcCtD
Nimodipine—Myalgia—Epirubicin—ovarian cancer	0.000529	0.00149	CcSEcCtD
Nimodipine—Nausea—Paclitaxel—ovarian cancer	0.000527	0.00148	CcSEcCtD
Nimodipine—Diarrhoea—Docetaxel—ovarian cancer	0.000514	0.00145	CcSEcCtD
Nimodipine—Felodipine—ABCB1—ovarian cancer	0.00051	0.151	CrCbGaD
Nimodipine—Palpitations—Doxorubicin—ovarian cancer	0.000508	0.00143	CcSEcCtD
Nimodipine—Oedema—Epirubicin—ovarian cancer	0.000507	0.00143	CcSEcCtD
Nimodipine—Nervous system disorder—Epirubicin—ovarian cancer	0.000497	0.0014	CcSEcCtD
Nimodipine—Dizziness—Docetaxel—ovarian cancer	0.000497	0.0014	CcSEcCtD
Nimodipine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000496	0.0014	CcSEcCtD
Nimodipine—Hypertension—Doxorubicin—ovarian cancer	0.000496	0.0014	CcSEcCtD
Nimodipine—Tachycardia—Epirubicin—ovarian cancer	0.000495	0.00139	CcSEcCtD
Nimodipine—Nifedipine—ABCB1—ovarian cancer	0.000493	0.147	CrCbGaD
Nimodipine—Hyperhidrosis—Epirubicin—ovarian cancer	0.00049	0.00138	CcSEcCtD
Nimodipine—Myalgia—Doxorubicin—ovarian cancer	0.000489	0.00138	CcSEcCtD
Nimodipine—Nicardipine—ABCB1—ovarian cancer	0.000485	0.144	CrCbGaD
Nimodipine—Vomiting—Docetaxel—ovarian cancer	0.000478	0.00135	CcSEcCtD
Nimodipine—Rash—Docetaxel—ovarian cancer	0.000474	0.00134	CcSEcCtD
Nimodipine—Hypotension—Epirubicin—ovarian cancer	0.000474	0.00134	CcSEcCtD
Nimodipine—Dermatitis—Docetaxel—ovarian cancer	0.000473	0.00133	CcSEcCtD
Nimodipine—Headache—Docetaxel—ovarian cancer	0.000471	0.00133	CcSEcCtD
Nimodipine—Oedema—Doxorubicin—ovarian cancer	0.000469	0.00132	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000462	0.0013	CcSEcCtD
Nimodipine—Nervous system disorder—Doxorubicin—ovarian cancer	0.00046	0.0013	CcSEcCtD
Nimodipine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000459	0.00129	CcSEcCtD
Nimodipine—Tachycardia—Doxorubicin—ovarian cancer	0.000458	0.00129	CcSEcCtD
Nimodipine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000453	0.00128	CcSEcCtD
Nimodipine—Dyspnoea—Epirubicin—ovarian cancer	0.000452	0.00127	CcSEcCtD
Nimodipine—Nausea—Docetaxel—ovarian cancer	0.000446	0.00126	CcSEcCtD
Nimodipine—Hypotension—Doxorubicin—ovarian cancer	0.000438	0.00124	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000438	0.00123	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000427	0.0012	CcSEcCtD
Nimodipine—Dyspnoea—Doxorubicin—ovarian cancer	0.000418	0.00118	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000405	0.00114	CcSEcCtD
Nimodipine—Hypersensitivity—Epirubicin—ovarian cancer	0.000373	0.00105	CcSEcCtD
Nimodipine—Pruritus—Epirubicin—ovarian cancer	0.000359	0.00101	CcSEcCtD
Nimodipine—Diarrhoea—Epirubicin—ovarian cancer	0.000347	0.000978	CcSEcCtD
Nimodipine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000346	0.000974	CcSEcCtD
Nimodipine—Dizziness—Epirubicin—ovarian cancer	0.000335	0.000945	CcSEcCtD
Nimodipine—Pruritus—Doxorubicin—ovarian cancer	0.000332	0.000935	CcSEcCtD
Nimodipine—Vomiting—Epirubicin—ovarian cancer	0.000322	0.000908	CcSEcCtD
Nimodipine—Diarrhoea—Doxorubicin—ovarian cancer	0.000321	0.000905	CcSEcCtD
Nimodipine—Rash—Epirubicin—ovarian cancer	0.00032	0.000901	CcSEcCtD
Nimodipine—Dermatitis—Epirubicin—ovarian cancer	0.000319	0.0009	CcSEcCtD
Nimodipine—Headache—Epirubicin—ovarian cancer	0.000318	0.000895	CcSEcCtD
Nimodipine—Dizziness—Doxorubicin—ovarian cancer	0.00031	0.000874	CcSEcCtD
Nimodipine—Nausea—Epirubicin—ovarian cancer	0.000301	0.000849	CcSEcCtD
Nimodipine—Vomiting—Doxorubicin—ovarian cancer	0.000298	0.000841	CcSEcCtD
Nimodipine—Rash—Doxorubicin—ovarian cancer	0.000296	0.000834	CcSEcCtD
Nimodipine—Dermatitis—Doxorubicin—ovarian cancer	0.000295	0.000833	CcSEcCtD
Nimodipine—Headache—Doxorubicin—ovarian cancer	0.000294	0.000828	CcSEcCtD
Nimodipine—Nausea—Doxorubicin—ovarian cancer	0.000279	0.000785	CcSEcCtD
Nimodipine—CACNB3—Axon guidance—KRAS—ovarian cancer	0.000191	0.000712	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—MAPK3—ovarian cancer	0.00019	0.000708	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—SLC2A1—ovarian cancer	0.000187	0.000699	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—KRAS—ovarian cancer	0.000186	0.000693	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—PPP2R1A—ovarian cancer	0.000184	0.000686	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PPP1CC—ovarian cancer	0.000183	0.000684	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—BRIP1—ovarian cancer	0.000183	0.000684	CbGpPWpGaD
Nimodipine—CACNB3—Neuronal System—HRAS—ovarian cancer	0.000183	0.000682	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—CTNNB1—ovarian cancer	0.000182	0.000679	CbGpPWpGaD
Nimodipine—CACNB2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	0.000182	0.000678	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—MAPK1—ovarian cancer	0.00018	0.000673	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—EGFR—ovarian cancer	0.00018	0.000673	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—CYP1B1—ovarian cancer	0.00018	0.00067	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—MMP9—ovarian cancer	0.000178	0.000666	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—MMP9—ovarian cancer	0.000178	0.000665	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—ERBB2—ovarian cancer	0.000178	0.000665	CbGpPWpGaD
Nimodipine—CACNB1—Neuronal System—HRAS—ovarian cancer	0.000178	0.000664	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—CTNNB1—ovarian cancer	0.000177	0.000661	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—MET—ovarian cancer	0.000174	0.000649	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—MMP9—ovarian cancer	0.000174	0.000648	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—KRAS—ovarian cancer	0.00017	0.000636	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—IL6ST—ovarian cancer	0.00017	0.000636	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—MMP2—ovarian cancer	0.000169	0.000631	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—MMP2—ovarian cancer	0.000169	0.000631	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—ERBB2—ovarian cancer	0.000169	0.000629	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—MET—ovarian cancer	0.000165	0.000614	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—HRAS—ovarian cancer	0.000162	0.000605	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—IL6ST—ovarian cancer	0.000161	0.000602	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—VEGFA—ovarian cancer	0.00016	0.000598	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—VEGFA—ovarian cancer	0.00016	0.000597	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—PPP2R1A—ovarian cancer	0.000159	0.000594	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—STAT3—ovarian cancer	0.000159	0.000592	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—NRAS—ovarian cancer	0.000158	0.000591	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—NRAS—ovarian cancer	0.000158	0.00059	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—HRAS—ovarian cancer	0.000158	0.000589	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—VEGFA—ovarian cancer	0.000156	0.000582	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—IL6—ovarian cancer	0.000155	0.000579	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—STAT3—ovarian cancer	0.000154	0.000576	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—NRAS—ovarian cancer	0.000154	0.000575	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—MMP9—ovarian cancer	0.000153	0.00057	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—MAPK3—ovarian cancer	0.000152	0.000566	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—MAPK3—ovarian cancer	0.000151	0.000565	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—IL6—ovarian cancer	0.000151	0.000564	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—ERBB2—ovarian cancer	0.000148	0.000553	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—ERBB2—ovarian cancer	0.000148	0.000553	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—ABCB1—ovarian cancer	0.000148	0.000552	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—YAP1—ovarian cancer	0.000148	0.000551	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—MAPK3—ovarian cancer	0.000147	0.00055	CbGpPWpGaD
Nimodipine—CACNB2—Transmission across Chemical Synapses—HRAS—ovarian cancer	0.000146	0.000544	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—TYMS—ovarian cancer	0.000145	0.000542	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—MMP2—ovarian cancer	0.000145	0.000541	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—HRAS—ovarian cancer	0.000145	0.00054	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—MET—ovarian cancer	0.000145	0.00054	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—MMP9—ovarian cancer	0.000145	0.00054	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—MAPK1—ovarian cancer	0.000144	0.000538	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—EGFR—ovarian cancer	0.000144	0.000538	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—MAPK1—ovarian cancer	0.000144	0.000537	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—NME2—ovarian cancer	0.000144	0.000537	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—EGFR—ovarian cancer	0.000144	0.000537	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—IL6ST—ovarian cancer	0.000142	0.000529	CbGpPWpGaD
Nimodipine—NR3C2—Generic Transcription Pathway—MYC—ovarian cancer	0.000141	0.000525	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—MAPK1—ovarian cancer	0.00014	0.000524	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—EGFR—ovarian cancer	0.00014	0.000523	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—YAP1—ovarian cancer	0.00014	0.000522	CbGpPWpGaD
Nimodipine—CACNB2—Neuronal System—MAPK1—ovarian cancer	0.000139	0.000519	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—IL6—ovarian cancer	0.000139	0.000517	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—MMP2—ovarian cancer	0.000137	0.000512	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—VEGFA—ovarian cancer	0.000137	0.000512	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—KRAS—ovarian cancer	0.000136	0.000508	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—KRAS—ovarian cancer	0.000136	0.000508	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—NRAS—ovarian cancer	0.000136	0.000506	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—KRAS—ovarian cancer	0.000133	0.000494	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—ESR1—ovarian cancer	0.00013	0.000486	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—VEGFA—ovarian cancer	0.00013	0.000485	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—MAPK3—ovarian cancer	0.00013	0.000484	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—CTNNB1—ovarian cancer	0.00013	0.000484	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—NRAS—ovarian cancer	0.000128	0.000479	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—AKT1—ovarian cancer	0.000128	0.000477	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—MMP9—ovarian cancer	0.000127	0.000474	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—MMP9—ovarian cancer	0.000127	0.000474	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—ERBB2—ovarian cancer	0.000127	0.000474	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—MAPK1—ovarian cancer	0.000124	0.000461	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—EGFR—ovarian cancer	0.000123	0.000461	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—YAP1—ovarian cancer	0.000123	0.000459	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—MAPK3—ovarian cancer	0.000123	0.000459	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—MMP2—ovarian cancer	0.000121	0.00045	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—FASN—ovarian cancer	0.00012	0.000449	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—ERBB2—ovarian cancer	0.00012	0.000449	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—SLC5A5—ovarian cancer	0.000118	0.000442	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—CAV1—ovarian cancer	0.000117	0.000437	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—MAPK1—ovarian cancer	0.000117	0.000436	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—EGFR—ovarian cancer	0.000117	0.000436	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—KRAS—ovarian cancer	0.000117	0.000435	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—HRAS—ovarian cancer	0.000116	0.000432	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—HRAS—ovarian cancer	0.000116	0.000431	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—SLC2A1—ovarian cancer	0.000114	0.000427	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—VEGFA—ovarian cancer	0.000114	0.000426	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—VEGFA—ovarian cancer	0.000114	0.000426	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—FASN—ovarian cancer	0.000114	0.000425	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—STAT3—ovarian cancer	0.000113	0.000422	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—NRAS—ovarian cancer	0.000113	0.000421	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—NRAS—ovarian cancer	0.000113	0.000421	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—HRAS—ovarian cancer	0.000113	0.00042	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—SLC5A5—ovarian cancer	0.000112	0.000419	CbGpPWpGaD
Nimodipine—CACNB2—Neuronal System—HRAS—ovarian cancer	0.000112	0.000417	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—CTNNB1—ovarian cancer	0.000111	0.000415	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—IL6—ovarian cancer	0.000111	0.000414	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—IL6—ovarian cancer	0.000111	0.000413	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—KRAS—ovarian cancer	0.00011	0.000412	CbGpPWpGaD
Nimodipine—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	0.00011	0.00041	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—CYP1B1—ovarian cancer	0.00011	0.000409	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—MMP9—ovarian cancer	0.000109	0.000407	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—SLC2A1—ovarian cancer	0.000108	0.000404	CbGpPWpGaD
Nimodipine—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000108	0.000404	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—MAPK3—ovarian cancer	0.000108	0.000403	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—MAPK3—ovarian cancer	0.000108	0.000403	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—IL6—ovarian cancer	0.000108	0.000402	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—PIK3CG—ovarian cancer	0.000107	0.000398	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—ERBB2—ovarian cancer	0.000106	0.000395	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—CTNNB1—ovarian cancer	0.000105	0.000393	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—CYP1B1—ovarian cancer	0.000104	0.000388	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—MMP9—ovarian cancer	0.000103	0.000385	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—MAPK1—ovarian cancer	0.000103	0.000383	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—EGFR—ovarian cancer	0.000103	0.000383	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—MAPK1—ovarian cancer	0.000103	0.000383	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—EGFR—ovarian cancer	0.000103	0.000383	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—AKT1—ovarian cancer	0.000102	0.000381	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—FASN—ovarian cancer	0.0001	0.000374	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—AKT1—ovarian cancer	9.95e-05	0.000371	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—HRAS—ovarian cancer	9.91e-05	0.00037	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—SLC5A5—ovarian cancer	9.86e-05	0.000368	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—VEGFA—ovarian cancer	9.79e-05	0.000365	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—PPP2R1A—ovarian cancer	9.73e-05	0.000363	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—KRAS—ovarian cancer	9.71e-05	0.000362	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—KRAS—ovarian cancer	9.71e-05	0.000362	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—STAT3—ovarian cancer	9.69e-05	0.000362	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—NRAS—ovarian cancer	9.67e-05	0.000361	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—SLC2A1—ovarian cancer	9.52e-05	0.000355	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—IL6—ovarian cancer	9.49e-05	0.000354	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—HRAS—ovarian cancer	9.39e-05	0.00035	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—PIK3CD—ovarian cancer	9.37e-05	0.00035	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—CYTB—ovarian cancer	9.28e-05	0.000346	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—VEGFA—ovarian cancer	9.27e-05	0.000346	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—MAPK3—ovarian cancer	9.26e-05	0.000346	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—CTNNB1—ovarian cancer	9.25e-05	0.000345	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—PPP2R1A—ovarian cancer	9.21e-05	0.000344	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—STAT3—ovarian cancer	9.18e-05	0.000342	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—NRAS—ovarian cancer	9.16e-05	0.000342	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—CYP1B1—ovarian cancer	9.13e-05	0.00034	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—MMP9—ovarian cancer	9.07e-05	0.000338	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—ABCB1—ovarian cancer	9.03e-05	0.000337	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—IL6—ovarian cancer	8.99e-05	0.000335	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—TYMS—ovarian cancer	8.87e-05	0.000331	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—MAPK1—ovarian cancer	8.81e-05	0.000329	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—EGFR—ovarian cancer	8.81e-05	0.000329	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—MAPK3—ovarian cancer	8.77e-05	0.000327	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—ABCB1—ovarian cancer	8.55e-05	0.000319	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—TYMS—ovarian cancer	8.4e-05	0.000313	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—MAPK1—ovarian cancer	8.35e-05	0.000311	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—EGFR—ovarian cancer	8.34e-05	0.000311	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—KRAS—ovarian cancer	8.32e-05	0.000311	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—HRAS—ovarian cancer	8.25e-05	0.000308	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—HRAS—ovarian cancer	8.25e-05	0.000308	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—PIK3CB—ovarian cancer	8.17e-05	0.000305	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—VEGFA—ovarian cancer	8.15e-05	0.000304	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—BRIP1—ovarian cancer	8.11e-05	0.000303	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PPP1CC—ovarian cancer	8.11e-05	0.000303	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PPP2R1A—ovarian cancer	8.1e-05	0.000302	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—STAT3—ovarian cancer	8.07e-05	0.000301	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—NRAS—ovarian cancer	8.05e-05	0.0003	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—IL6—ovarian cancer	7.9e-05	0.000295	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—IL6—ovarian cancer	7.9e-05	0.000295	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—KRAS—ovarian cancer	7.88e-05	0.000294	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—MAPK3—ovarian cancer	7.71e-05	0.000288	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—ABCB1—ovarian cancer	7.52e-05	0.00028	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—TYMS—ovarian cancer	7.38e-05	0.000275	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—MAPK1—ovarian cancer	7.33e-05	0.000274	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—EGFR—ovarian cancer	7.33e-05	0.000274	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—AKT1—ovarian cancer	7.29e-05	0.000272	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—CAV1—ovarian cancer	7.15e-05	0.000267	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—HRAS—ovarian cancer	7.08e-05	0.000264	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—PTEN—ovarian cancer	7.06e-05	0.000263	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—MAPK3—ovarian cancer	6.96e-05	0.00026	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—KRAS—ovarian cancer	6.93e-05	0.000258	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—IL6—ovarian cancer	6.77e-05	0.000253	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—MYC—ovarian cancer	6.77e-05	0.000253	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—CAV1—ovarian cancer	6.77e-05	0.000253	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—HRAS—ovarian cancer	6.7e-05	0.00025	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—NME2—ovarian cancer	6.7e-05	0.00025	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—PIK3CG—ovarian cancer	6.51e-05	0.000243	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—IL6—ovarian cancer	6.41e-05	0.000239	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—AKT1—ovarian cancer	6.25e-05	0.000233	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—PIK3CG—ovarian cancer	6.17e-05	0.00023	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—CAV1—ovarian cancer	5.95e-05	0.000222	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—AKT1—ovarian cancer	5.92e-05	0.000221	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—HRAS—ovarian cancer	5.89e-05	0.00022	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—PIK3CD—ovarian cancer	5.72e-05	0.000214	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—IL6—ovarian cancer	5.63e-05	0.00021	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—YAP1—ovarian cancer	5.44e-05	0.000203	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—PIK3CD—ovarian cancer	5.42e-05	0.000202	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PIK3CG—ovarian cancer	5.42e-05	0.000202	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—AKT1—ovarian cancer	5.2e-05	0.000194	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—PIK3CB—ovarian cancer	4.99e-05	0.000186	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—PIK3CA—ovarian cancer	4.98e-05	0.000186	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PIK3CD—ovarian cancer	4.76e-05	0.000178	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—PIK3CB—ovarian cancer	4.73e-05	0.000176	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—AKT1—ovarian cancer	4.7e-05	0.000175	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—FASN—ovarian cancer	4.44e-05	0.000165	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—SLC5A5—ovarian cancer	4.36e-05	0.000163	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—CYTB—ovarian cancer	4.32e-05	0.000161	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—PTEN—ovarian cancer	4.31e-05	0.000161	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—SLC2A1—ovarian cancer	4.21e-05	0.000157	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PIK3CB—ovarian cancer	4.15e-05	0.000155	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—PTEN—ovarian cancer	4.08e-05	0.000152	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—AKT1—ovarian cancer	4.07e-05	0.000152	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—CYP1B1—ovarian cancer	4.04e-05	0.000151	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—BRIP1—ovarian cancer	3.77e-05	0.000141	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PPP1CC—ovarian cancer	3.77e-05	0.000141	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PTEN—ovarian cancer	3.59e-05	0.000134	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	3.58e-05	0.000134	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—ABCB1—ovarian cancer	3.33e-05	0.000124	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—TYMS—ovarian cancer	3.27e-05	0.000122	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—PIK3CA—ovarian cancer	3.04e-05	0.000113	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—PIK3CA—ovarian cancer	2.88e-05	0.000107	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—CAV1—ovarian cancer	2.63e-05	9.82e-05	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PIK3CA—ovarian cancer	2.53e-05	9.44e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—YAP1—ovarian cancer	2.53e-05	9.44e-05	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—AKT1—ovarian cancer	2.48e-05	9.27e-05	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PIK3CG—ovarian cancer	2.4e-05	8.95e-05	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—AKT1—ovarian cancer	2.35e-05	8.78e-05	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PIK3CD—ovarian cancer	2.11e-05	7.87e-05	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—AKT1—ovarian cancer	2.07e-05	7.71e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—FASN—ovarian cancer	2.06e-05	7.69e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.03e-05	7.57e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.96e-05	7.31e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.88e-05	7.01e-05	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PIK3CB—ovarian cancer	1.84e-05	6.86e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.67e-05	6.21e-05	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PTEN—ovarian cancer	1.59e-05	5.92e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.55e-05	5.77e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—TYMS—ovarian cancer	1.52e-05	5.67e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—CAV1—ovarian cancer	1.22e-05	4.57e-05	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.12e-05	4.18e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.12e-05	4.16e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	9.8e-06	3.66e-05	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—AKT1—ovarian cancer	9.15e-06	3.41e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	8.54e-06	3.19e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PTEN—ovarian cancer	7.38e-06	2.75e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	5.21e-06	1.94e-05	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—AKT1—ovarian cancer	4.25e-06	1.59e-05	CbGpPWpGaD
